source
- Context Therapeutics drops CT-95 bispecific T-cell engager to stretch cash runway to 2027Context Therapeutics announced it is halting development of its bispecific T-cell engager CT-95. The company acquired CT-95 in 2024 for $3.7 million and began dosing patients in a phase 1 trial in…
- Actimed regains full rights to S-oxprenolol, ends $126 million Faraday licensing dealActimed Therapeutics announced it has reclaimed all worldwide rights to its experimental wasting disease drug S-oxprenolol, terminating the licensing agreement it had with Faraday Pharmaceuticals.…